Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Net Income towards Common Stockholders Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - | -38.56% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 62.15% |
| 10 | Incyte | 25.62 Bn | 21.08 Bn | 1.57 Bn | 42.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.44% |
| Mar 31, 2026 | 47.10% |
| Dec 31, 2025 | 36.40% |
| Sep 30, 2025 | 39.61% |
| Jun 30, 2025 | 36.14% |
| Mar 31, 2025 | 57.65% |
| Dec 31, 2024 | 31.31% |
| Sep 30, 2024 | 18.29% |
| Jun 30, 2024 | 55.34% |
| Mar 31, 2024 | 30.95% |
| Dec 31, 2023 | 17.28% |
| Sep 30, 2023 | 37.21% |
| Jun 30, 2023 | -15.48% |
| Mar 31, 2023 | 1.51% |
| Dec 31, 2022 | 9.09% |
| Sep 30, 2022 | -24.86% |
| Jun 30, 2022 | -8.12% |
| Mar 31, 2022 | -9.73% |
| Dec 31, 2021 | -6.92% |
| Sep 30, 2021 | 5.88% |